The Effect on Treatment Comparisons of Different Measurement Frequencies in Human Immunodeficiency Virus Observational Databases
Open Access
- 16 February 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 163 (7), 676-683
- https://doi.org/10.1093/aje/kwj083
Abstract
Data collected in a routine clinical setting are frequently used to compare antiretroviral treatments for human immunodeficiency virus (HIV). Differences in the frequency of measurement of HIV RNA levels and CD4-positive T-lymphocyte cell counts introduce a possible source of bias into estimates of the difference in effectiveness between treatments. The authors investigated the size of this bias when survival analysis methods are used to compare the initial efficacy of antiretroviral regimens. Data sets of clinical markers were simulated by use of differential equations that model the interaction between HIV and human T-cells. Cox proportional hazards and parametric models were fitted to the simulated data sets to evaluate the bias and coverage of 95% confidence intervals for the difference between regimens. The authors' results demonstrate that differences in the frequency of follow-up can substantially bias estimated treatment differences if methods do not correctly account for the intervals between measurements and if the statistical model chosen does not fit the data well. Analyses using methods applicable to interval-censored data reduce the bias. In the Athena cohort of HIV-infected individuals in the Netherlands from 1999 to 2003, there are differences in measurement frequency between current regimens that are of sufficient magnitude to conclude incorrectly that some regimens are more effective than others.Keywords
This publication has 18 references indexed in Scilit:
- Mortality and progression to AIDS after starting highly active antiretroviral therapyAIDS, 2003
- Virological rebound after suppression on highly active antiretroviral therapyAIDS, 2003
- Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effectsStatistics in Medicine, 2002
- Quantification of intrinsic residual viral replication in treated HIV-infected patientsProceedings of the National Academy of Sciences of the United States of America, 2001
- The role of antigenic stimulation and cytotoxic T cell activity in regulating the long–term immunopathogenesis of HIV: mechanisms and clinical implicationsProceedings Of The Royal Society B-Biological Sciences, 2001
- Comparison of Virologic, Immunologic, and Clinical Response to Five Different Initial Protease Inhibitor-Containing and Nevirapine-Containing RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entryNature Medicine, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Informative Drop-Out in Longitudinal Data AnalysisJournal of the Royal Statistical Society Series C: Applied Statistics, 1994
- A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effectMathematical Modelling, 1986